UK Approved The Use Of Remdesivir To Treat Some COVID-19 Patients

1. Huateng Pharma https://en.huatengsci.com UK Approved The Use Of Remdesivir To Treat Some COVID-19 Patients Recently, the Department of Health and Social Care of UK announced that the antiviral drug Remdesivir will be used for patients with COVID-19 that meet certain clinical standards to help them recover. Clinical trials for Remdesivir are being carried out in the UK and globally. Early data shows that the drug can shorten the recovery time of patients by about 4 days. The opinion of the Early access to medicines scheme (EAMS) and Medicines and the Healthcare products Regulatory Agency (MHRA) supports the treatment of Remdesivir for NHS patients who meet specific clinical conditions. At present, due to the limited supply of Remdesivir, only a part of patients who are likely to achieve the greatest benefit will be treated by priority. Lord Bethell, British Minister of Innovation, said: "This is a huge progress we have made. In this unprecedented period, we must be at the forefront of medical development while always putting patient safety first. We make decisions with the latest, professional scientific advice at the heart and will continue to monitor the success of clinical trials across the country to ensure the best results for patients in the UK."

2. Huateng Pharma https://en.huatengsci.com About Remdesivir Remdesivir is a nucleotide analogue under study with broad-spectrum antiviral activity, which has shown efficacy in a variety of emerging viral pathogens including Ebola Viruses, Marburg virus, Middle East respiratory syndrome (MERS) and SARS. An in vitro test conducted by Gilead showed that Remdesivir is active against SARS-CoV-2. Several ongoing phase III clinical trials are evaluating the safety and efficacy of Remdesivir in the treatment of COVID-19. How does it work? Remdesivir is a member of the most important class of drugs (called nucleoside analogs). Currently, there are more than 30 of these drugs have been approved for the treatment of viruses, parasites, cancer and bacterial infections. The drug works by stopping or interrupting virus replication, thereby preventing the virus from multiplying and infecting more cells in the body. In the case of coronavirus infection, the drug works by blocking RNA polymerase, which is one of the vital enzymes required for viruses to replicate their genetic material and reproduce in the body. Huateng Pharma, a leading intermediates manufacturers in China, is exclusively focusing on manufacturing API's Intermediates, such as Baloxavir Marboxil intermediates, Remdesivir intermediates, Favipiravir intermediates, Semaglutide intermediates and so on. We are able to provide the production of these intermediates for research use with capacities varying from gram to kilograms with high purity to our customers all over the world. Reference: This article is based on an English Press Release issued by the Department of Health and Social Care of UK on 26 May.